| Literature DB >> 29173787 |
Elizabeth A Spencer1, Marla C Dubinsky2.
Abstract
Clinical trials for the most effective drugs in the armamentarium of medications for inflammatory bowel disease (IBD) have shown only a 50-60% response rate, and this drops to 30% in maintenance. However, therapeutic drug monitoring (TDM) to adjust dosing to account for patient-specific characteristics, which has been shown to improve outcomes, was not utilized in these trials. This review will detail the development of TDM within the IBD space as it evolved from thiopurines to biologics and continues to evolve with loftier treat-to-target goals and more sophisticated dashboard systems.Entities:
Keywords: Biologics; Inflammatory bowel disease; Therapeutic drug monitoring; Thiopurine metabolite monitoring
Mesh：
Substances：
Year: 2017 PMID： 29173787 DOI： 10.1016/j.pcl.2017.08.008
Source DB: PubMed Journal: Pediatr Clin North Am ISSN： 0031-3955 Impact factor: 3.278